Edition:
India

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

51.99USD
11:22pm IST
Change (% chg)

$-0.34 (-0.65%)
Prev Close
$52.33
Open
$52.45
Day's High
$52.45
Day's Low
$51.37
Volume
26,114
Avg. Vol
117,452
52-wk High
$55.94
52-wk Low
$32.96

Chart for

About

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $1,669.07
Shares Outstanding(Mil.): 41.21
Dividend: --
Yield (%): --

Financials

  EBS.N Industry Sector
P/E (TTM): 29.50 30.95 32.74
EPS (TTM): 1.37 -- --
ROI: 7.33 14.84 14.38
ROE: 10.48 16.34 16.08

BRIEF-Emergent BioSolutions Reports Q1 Adjusted Loss Per Share $0.03

* EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

04 May 2018

BRIEF-Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer​

* EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY

27 Mar 2018

BRIEF-Emergent Biosolutions To Implement Stock Repurchase Program

* EMERGENT BIOSOLUTIONS TO IMPLEMENT STOCK REPURCHASE PROGRAM FOR UP TO $50 MILLION OF ITS COMMON STOCK

23 Mar 2018

BRIEF-Emergent Biosolutions Awarded One-Year CDC Contract Valued At $26 Mln

* EMERGENT BIOSOLUTIONS AWARDED ONE-YEAR CDC CONTRACT VALUED AT $26 MILLION FOR VACCINIA IMMUNE GLOBULIN PROGRAM

28 Feb 2018

BRIEF-Emergent Biosolutions And Valneva Initiate Clinical Study To Evaluate Vaccine Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

27 Feb 2018

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

27 Feb 2018

BRIEF-Emergent BioSolutions Q4 Earnings Per Share $0.67

* EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2017 FINANCIAL RESULTS

23 Feb 2018

BRIEF-Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million

* EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK

08 Jan 2018

Competitors

Earnings vs. Estimates